Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech ...

Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Under the terms of the collaboration, Iktos will apply its generative AI and AI-orchestrated robotics platform to design, synthesize, and optimize small molecules for multiple undisclosed targets.

Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...

The American Society for Radiation Oncology (ASTRO) announced today that it rebranded its research foundation, formerly the ...

Boston-based Aktis Oncology has filed to go public in the U.S., according to multiple news reports. The company has operations in Durham.

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

Tango Therapeutics has announced that founding CEO Dr. Barbara Weber retired on January 8, 2026, transitioning to Executive Chair while board member Dr. Malte Peters, a physician with extensive ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

The one-and-a-half-day symposium will provide an overview of recent advances in the treatment of solid tumors with novel ...